Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update
Work
Year: 2022
Type: article
Abstract: ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an ... more
Source: Journal of Clinical Oncology
Institutions National Cancer Institute, American Society of Clinical Oncology, Columbia University Irving Medical Center
Cites: 2
Cited by: 34
Related to: 10
FWCI: 5.432
Citation percentile (by year/subfield): 82.09
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Good health and well-being
Open Access status: bronze